Showing results (1-10 of 1,109) with videos related to
Sort By:
Pageof 111
American Journal of Therapeutics|January 15, 2016
Statistical Primer on Biosimilar Clinical DevelopmentLeah Isakov, Bo Jin, Ira Allen JacobsSeminars in Oncology|February 25, 2014
Biosimilar safety considerations in clinical practiceEdwin Choy, Ira Allen JacobsSeminars in Oncology|April 29, 2014
Biosimilars in oncology: from development to clinical practiceKatherine H Rak Tkaczuk, Ira Allen JacobsPharmacoeconomics|June 30, 2017
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact AnalysisSteven Simoens, Ira Jacobs, Robert Popovian, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 26, 2016
Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published EvidenceIra Jacobs, Danielle Petersel, Leah Isakov, et al.Journal of Clinical Microbiology|June 5, 2020
Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization AssaysMarten Heeringa, Brett Leav, Igor Smolenov, et al.Vaccine|February 13, 2025
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and olderBrandon J Essink, Wim Vermeulen, Coralie Andrade, et al.Plos One|December 28, 2020
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidatesDonald A Berry, Scott Berry, Peter Hale, et al.Vaccines|October 28, 2023
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of AgeAiri Poder, Janine Oberije, Jay Meyer, et al.The Lancet. Respiratory Medicine|April 11, 2018
Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trialTimo Vesikari, Judith Kirstein, Grace Devota Go, et al.Pageof 111